BioArctic AB/Skr BIOA B
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About BioArctic AB
BioArctic AB is a Swedish biopharmaceutical company focusing on developing treatments for central nervous system disorders. The company is notably engaged in the research and development of therapies for neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. Founded in 2003, BioArctic collaborates with academic institutions and global pharmaceutical companies to advance its innovative approaches. The company is headquartered in Stockholm, Sweden, and leverages its strategic partnerships and scientific expertise to address unmet medical needs in its chosen field. BioArctic's competitive strengths include its proprietary technology platforms and strong intellectual property portfolio.
- Ticker
- Skr BIOA B
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 150
- Headquarters
- Stockholm, Sweden
- Website
- www.bioarctic.se
BioArctic AB Metrics
BasicAdvanced
kr 28B
267.15
kr 1.18
-0.68
kr 2.00
0.63%
Price and volume
Market cap
kr 28B
Beta
-0.68
52-week high
kr 364.40
52-week low
kr 257.00
Average daily volume
112K
Dividend rate
kr 2.00
Financial strength
Current ratio
3.992
Quick ratio
2.967
Long term debt to equity
0.036
Total debt to equity
0.045
Profitability
Gross margin (TTM)
93.17%
Net profit margin (TTM)
10.53%
Operating margin (TTM)
19.62%
Effective tax rate (TTM)
57.56%
Revenue per employee (TTM)
kr 6,680,000
Management effectiveness
Return on assets (TTM)
4.78%
Return on equity (TTM)
5.21%
Valuation
Price to earnings (TTM)
267.151
Price to revenue (TTM)
27.977
Price to book
13.96
Price to tangible book (TTM)
13.96
Price to free cash flow (TTM)
119.993
Free cash flow yield (TTM)
0.83%
Free cash flow per share (TTM)
2.637
Dividend yield (TTM)
0.63%
Forward dividend yield
0.63%
Growth
Revenue change (TTM)
-46.09%
Earnings per share change (TTM)
-90.14%
3-year revenue growth (CAGR)
17.57%
3-year earnings per share growth (CAGR)
-26.96%
Bulls say / Bears say
The US approval and launch of a weekly, at-home Leqembi autoinjector, alongside China’s approval, gives patients an easier alternative to clinic infusions. If that convenience brings more patients into treatment, it could support sales growth. (PR Newswire, BioArctic)
A research deal with Eli Lilly brings BioArctic a USD 30 million upfront payment and the potential for up to USD 770 million in milestones, plus royalties. It gives the BrainTransporter platform a further route to generate value beyond Leqembi. (BioArctic)
Profitability is under pressure as BioArctic invests in development: it reported a SEK 6.5 million operating loss in Q2 and expects operating costs to rise 40–60% in 2026. Higher royalties may therefore not translate quickly into stronger earnings. (BioArctic)
Leqembi royalties made up about 72% of Q2 net revenue, leaving BioArctic heavily exposed to one drug’s sales. Any slowdown in Leqembi uptake would have a material effect on the company’s revenue base. (BioArctic)
Data summarised monthly by Lightyear AI. Last updated on 27 Oct 2026.
BioArctic AB Financial Performance
Revenues and expenses
BioArctic AB Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing BioArctic AB
Fund name | Fund size | Skr BIOA B weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.13% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.13% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.13% |
iShares Ageing Population$AGED | $953M | 0.12% |
iShares Ageing Population£AGES | $953M | 0.12% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.